Progress of Nimotuzumab Application in Nasopharyngeal Carcinoma

VernacularTitle:尼妥珠单抗在鼻咽癌治疗中的应用进展
Author: Tianci LIANG ^{1
,

2} ; Yue ZHAO ^{1
,

2} ; Chenchen SONG ^{1
,

2} ; Chaoyi ZHANG ^{1
,

2} ; Chen CHEN ^{1
,

2} ; Qiaoran LI ^{1
,

2} ; Biaoxue RONG ³
Author Information

1. Department of Oncology, The First Affiliated Hospital of Xi'an Medical University, Xi'an 710077, China
2. Graduate School of Xi'an Medical University, Xi'an 710077, China.
3. Department of Oncology, The First Affiliated Hospital of Xi'an Medical University, Xi'an 710077, China.
Publication Type:REVIEW
Keywords: Nasopharyngeal carcinoma; Nimotuzumab; Epidermal growth factor receptor; Targeted therapy; Antitumor treatment
From: Cancer Research on Prevention and Treatment 2024;51(11):956-961
CountryChina
Language:Chinese
Abstract: Compared with the global average, the incidence rate of nasopharyngeal carcinoma (NPC) in China is higher, particularly in the southern regions where the mortality rate has remained persistently high. Nimotuzumab, a targeted therapy that acts on the epidermal growth factor receptor, has prompted continuous progress in NPC treatment. The combination of nimotuzumab with traditional radiotherapy and chemotherapy can enhance treatment efficacy, reduce adverse reactions, and improve patients’ quality of life. This article summarizes current research findings from this perspective to provide diagnostic and therapeutic strategies for NPC treatment.